Abstract：
Current antiretroviral regimens have, for the most part, achieved optimal antiretroviral efficacy and tolerability, transforming HIV infection from a deadly disease into a manageable chronic condition. However, adherence to daily oral drug intake remains an issue, as it is the most important determinant for sustained viral suppression and prevention of the emergence of drug-resistant viral strains. The long-acting injection antiretroviral cabotegravir and rilpivirine combination, a novel drug delivery approach, is about to revolutionise the therapy for people living with HIV. In this protocol, we aim to generate a clinically useful summary of the interventions based on their efficacy.
We searched the literature for eligible studies published from inception up to 16 August 2022 through PubMed, EMBASE, Cochrane Library, Scopus and ClinicalTrials.gov. Two methodologically trained researchers will select the qualified studies for data extraction independently. Cochrane Risk of Bias tool will be used to assess the risk of bias in included studies. Statistical heterogeneity will be computed by Cochrane X2 and I2 tests. Sensitivity analysis will be conducted to evaluate the stability of the results. Publication biases will be evaluated by Begg\'s and Egger\'s tests. The quality of evidence will be assessed by the Grading of Recommendations Assessment, Development and Evaluation system. The RevMan V.5.3 and Stata V.14.0 software will be applied for statistical analyses.
Ethical approval will not be required for this systematic review because the data used are not linked to the individual patient. The results of this review will be disseminated by being published in a peer-reviewed journal.
CRD42022310414.
We searched the literature for eligible studies published from inception up to 16 August 2022 through PubMed, EMBASE, Cochrane Library, Scopus and ClinicalTrials.gov. Two methodologically trained researchers will select the qualified studies for data extraction independently. Cochrane Risk of Bias tool will be used to assess the risk of bias in included studies. Statistical heterogeneity will be computed by Cochrane X2 and I2 tests. Sensitivity analysis will be conducted to evaluate the stability of the results. Publication biases will be evaluated by Begg\'s and Egger\'s tests. The quality of evidence will be assessed by the Grading of Recommendations Assessment, Development and Evaluation system. The RevMan V.5.3 and Stata V.14.0 software will be applied for statistical analyses.
Ethical approval will not be required for this systematic review because the data used are not linked to the individual patient. The results of this review will be disseminated by being published in a peer-reviewed journal.
CRD42022310414.
摘要：
背景：目前的抗逆转录病毒疗法，在大多数情况下，实现了最佳的抗逆转录病毒疗效和耐受性，将HIV感染从致命疾病转变为可控制的慢性病。然而,坚持每日口服药物摄入仍然是一个问题，因为它是持续抑制病毒和预防耐药病毒株出现的最重要决定因素。长效注射抗逆转录病毒Cabotegravir和利匹韦林组合，一种新的药物递送方法，即将彻底改变艾滋病毒感染者的治疗方法。在这个协议中,我们的目标是根据干预措施的疗效对其进行临床有用的总结.
方法：我们搜索了从开始到2022年8月16日通过PubMed发表的合格研究的文献，EMBASE,科克伦图书馆,ScopusandClinicalTrials.gov.两名经过方法学训练的研究人员将独立选择合格的研究进行数据提取。Cochrane偏差风险工具将用于评估纳入研究的偏差风险。统计异质性将通过CochraneX2和I2检验来计算。将进行敏感性分析以评估结果的稳定性。出版偏见将通过Begg\和Egger\的测试来评估。证据质量将通过建议分级评估来评估，开发和评估系统。将应用RevManV.5.3和StataV.14.0软件进行统计分析。
背景：本系统评价不需要伦理批准，因为所使用的数据与患者个体无关。本评论的结果将通过发表在同行评审的期刊上进行传播。
UNASSIGNED：CRD42022310414。
方法：我们搜索了从开始到2022年8月16日通过PubMed发表的合格研究的文献，EMBASE,科克伦图书馆,ScopusandClinicalTrials.gov.两名经过方法学训练的研究人员将独立选择合格的研究进行数据提取。Cochrane偏差风险工具将用于评估纳入研究的偏差风险。统计异质性将通过CochraneX2和I2检验来计算。将进行敏感性分析以评估结果的稳定性。出版偏见将通过Begg\和Egger\的测试来评估。证据质量将通过建议分级评估来评估，开发和评估系统。将应用RevManV.5.3和StataV.14.0软件进行统计分析。
背景：本系统评价不需要伦理批准，因为所使用的数据与患者个体无关。本评论的结果将通过发表在同行评审的期刊上进行传播。
UNASSIGNED：CRD42022310414。
